The stock price of GH Research PLC (NASDAQ: GHRS) has jumped by 12.89 compared to previous close of 9.54. Despite this, the company has seen a gain of 13.37% in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025 Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UK Full response to the IND hold on track for submission in mid-2025 Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024 Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the year ended December 31, 2024, and provided updates on its business. Business Updates GH001 in Patients with TRD GH001, our proprietary inhalable mebufotenin product candidate, is currently being investigated in a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial in approximately 80 patients with treatment-resistant depression (TRD) (GH001-TRD-201).
Is It Worth Investing in GH Research PLC (NASDAQ: GHRS) Right Now?
Moreover, the 36-month beta value for GHRS is 0.86. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GHRS is 40.44M and currently, short sellers hold a 7.12% of that float. On May 02, 2025, GHRS’s average trading volume was 529.29K shares.
GHRS’s Market Performance
The stock of GH Research PLC (GHRS) has seen a 13.37% increase in the past week, with a 0.09% rise in the past month, and a 11.15% gain in the past quarter. The volatility ratio for the week is 8.56%, and the volatility levels for the past 30 days are at 8.49% for GHRS. The simple moving average for the past 20 days is 15.37% for GHRS’s stock, with a 11.44% simple moving average for the past 200 days.
Analysts’ Opinion of GHRS
Many brokerage firms have already submitted their reports for GHRS stocks, with Guggenheim repeating the rating for GHRS by listing it as a “Buy.” The predicted price for GHRS in the upcoming period, according to Guggenheim is $32 based on the research report published on March 13, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see GHRS reach a price target of $31. The rating they have provided for GHRS stocks is “Outperform” according to the report published on March 07th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to GHRS, setting the target price at $14 in the report published on February 13th of the current year.
GHRS Trading at 2.61% from the 50-Day Moving Average
After a stumble in the market that brought GHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.46% of loss for the given period.
Volatility was left at 8.49%, however, over the last 30 days, the volatility rate increased by 8.56%, as shares surge +3.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.02% lower at present.
During the last 5 trading sessions, GHRS rose by +13.37%, which changed the moving average for the period of 200-days by -7.63% in comparison to the 20-day moving average, which settled at $9.34. In addition, GH Research PLC saw 53.86% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for GHRS
Current profitability levels for the company are sitting at:
- -628.27 for the present operating margin
- -0.97 for the gross margin
The net margin for GH Research PLC stands at -487.01. The total capital return value is set at -0.28. Equity return is now at value -19.58, with -18.80 for asset returns.
Based on GH Research PLC (GHRS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -67.76. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -70.1.
Currently, EBITDA for the company is -37.93 million with net debt to EBITDA at 2.63. When we switch over and look at the enterprise to sales, we see a ratio of 7098.45. The receivables turnover for the company is 0.53for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.23.
Conclusion
To wrap up, the performance of GH Research PLC (GHRS) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
